Warfarin Prescribing - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

Warfarin Prescribing

Description:

Our vision: Healthier communities, Excellence in ... 2 brands: Coumadin (1 mg, 2 mg and 5 mg) and Marevan (1 mg, 3 mg and 5 mg) ... Known bleeding diathesis ... – PowerPoint PPT presentation

Number of Views:140
Avg rating:3.0/5.0
Slides: 23
Provided by: hne7
Category:

less

Transcript and Presenter's Notes

Title: Warfarin Prescribing


1
Warfarin Prescribing
  • Presented by Sally Marotti
  • Prepared by Jennifer MacDonald
  • July 2008

2
Warfarin Sodium
  • 2 brands Coumadin (1 mg, 2 mg and 5 mg) and
    Marevan (1 mg, 3 mg and 5 mg) DONT
    SUBSTITUTE as not bioequivalent
  • High risk medication (narrow therapeutic range)
  • Too much bleed
  • Too little clot
  • Patients have variable responses to treatment
  • Goal for initiation
  • Rapidly attain a stable therapeutic INR without
    over-anticoagulation

3
Monitoring INR (International Normalised Ratio)
  • Target INR 3.0 4.5 older mechanical heart
    valves
  • 2.5 3.5 newer mechanical heart valves
  • 2.0 3.0 other indications
  • Determine INR on day 1 then daily or on
    alternate days until stable
  • Dosage changes not reflected fully in INR for 2-3
    days

4
National Inpatient Medication Chart
2-3
PE
  • The warfarin ordering section is printed in red
    as an extra alert to indicate that it is an
    anticoagulant (and a high-risk medicine).
  • Standard dose time of 1600 hours (4pm) - allows
    the medical team caring for the patient to order
    the next dose based on INR results, rather than
    leaving it for after-hours staff to do PLUS INR
    tested 16 hours post (8am).
  • The indication and target INR should be included
    when warfarin is initially ordered.

5
National Inpatient Medication Chart
30/10
1.1
10
2-3
po
PE
MC
Imprest
RN CN
Dr Marevan
2310
  • For each day of therapy, the following
    information should be documented
  • INR result
  • warfarin dose
  • doctors initials
  • initials of nurse that administers the dose and
    the checking nurse
  • Pharmacists will also annotate the chart when
    possible

6
Warfarin Chart Audit
  • 21 patients on warfarin at JHH who had 342 days
    of warfarin charted on 65 medication charts
  • 16 doses were not given (5). 10 of these did not
    have the dose charted by the medical officer and
    nursing staff therefore did not administer
  • 31 (9) doses did not have the dose signed by the
    medical officer
  • 27 INR results were not documented on the charts
  • Indication not recorded in 55, target INR not
    recorded in 15

7
Warfarin Chart Audit
  • Time to therapeutic INR for some patients was
    excessive (12 days)
  • The use of the eighth day of the chart for
    warfarin creates issues for other medications
    with pm dosing as nursing staff are unable to
    sign when administered
  • Nomenclature and signing for doses to be withheld
    was poor (w/h, X, 0mg etc)

8
Age Adjusted Warfarin Initiation Protocol
  • Developed trialled by Haematology
    Pharmacology JHH QUMC approved
  • Rapid achievement of a stable INR with minimal
    over-anticoagulation
  • Coped with other variables shown to affect
    maintenance warfarin dosing, such as weight,
    gender, pharmacologic factors affecting
    clearance, and risk factors.
  • NOTE does not replace thinking!!

9
Age Adjusted Warfarin Initiation Protocol
  • Day 1 INR reflects pre-warfarin baseline. If
    gt1.4, reasons for coagulopathy should be
    assessed.
  • Warfarin doses on Days 2-4 are based on INR
    measured 16hrs after the previous days dose
  • Patients with low albumin may be particularly
    sensitive to the anti-coagulation effects of
    warfarin
  • Consider decreasing dose by around one third if
    the patient has one or more of the following
  • Severe congestive cardiac failure (ejection
    fraction lt30 and/or biventricular failure)
  • Severe airways disease (oxygen/steroid dependent
    or dyspnoea at rest)
  • Concurrent amiodarone

10
Age-adjusted warfarin initiation protocol
11
Safe warfarin prescribing
  • Prescribe and sign EACH days doses
  • Look up and write INR results on charts
  • Include INR target indication when prescribing
  • Use the Age Adjusted Warfarin protocol
  • Endorse doses to be withheld as w/h and sign
  • Do not use the eighth day column

12
CAPAC (Community Acute/Post Acute Care Service)
  • Referral for anticoagulation in the community

Non-clinical exclusion criteria
  • Less than 16 years of age (parent/guardian
    consent required if lt18)
  • Resides outside CAPAC catchment area
  • Not able to transfer and mobilise
    independently
  • Patient unable to obtain adequate rest and
    nutritionNo access to telephone
  • Home environment not safe for health care
    worker home visits
  • Patient behaviours not safe for health care
    worker home visits
  • Does not agree to CAPAC providing treatment
    at home

Clinical Exclusion Criteria - General
13
Case Study One
  • 32 year old (65kg) patient Lisa Thrombus presents
    to hospital with severe leg pain and is diagnosed
    with a DVT
  • She is commenced on warfarin po and enoxaparin
    100mg sc daily
  • Her day 1 baseline INR is 1.1
  • Fill out the chart provided to reflect this
    information

14
Case Study One
30/10
1.1
10
2-3
po
DVT
MC
RN CN
Dr Marevan
2310
  • On day two you measure her INR at 8am (16 hours
    post dose) and the result returns as 1.8
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

15
Case Study One
30/10
1.1
1.8
10
0.5
2-3
po
DVT
MC
MC
RN CN
Dr Marevan
2310
  • On day three you measure her INR at 8am and the
    results return as 1.6
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

16
Case Study One
30/10
1.1
1.8
1.6
10
0.5
10
2-3
po
DVT
MC
MC
MC
RN CN
RN CN
Dr Marevan
2310
  • On day four you measure her INR at 8am and the
    results return as 2.5
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

17
Case Study One
30/10
1.1
1.8
1.6
2.5
10
0.5
10
5
2-3
po
DVT
MC
MC
MC
MC
RN CN
RN CN
RN CN
Dr Marevan
2310
  • A 4.5mg 5.5mg dose range is appropriate

18
Case Study Two
  • 78 year old (85kg) patient Maurice Embolus
    presents to hospital with SOB and chest pain. He
    is diagnosed with a pulmonary embolus.
  • He is commenced on warfarin and heparin 5000
    units IV bolus followed by IV infusion 1000-2000
    units/hr adjusted according to APTT until
    therapeutic
  • His pre-warfarin baseline INR is 1.2
  • Fill out the chart provided to reflect this
    information

19
Case Study Two
30/10
1.2
7.5
2-3
po
PE
MC
RN CN
Dr Marevan
2310
  • On day two you measure his INR at 8am (16 hours
    post dose) and the result returns as 1.6
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

20
Case Study Two
30/10
1.1
1.6
7.5
0.5
2-3
po
DVT
MC
MC
RN CN
Dr Marevan
2310
  • On day three you measure his INR at 8am and the
    results return as 2.2
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

21
Case Study Two
30/10
1.1
1.8
2.2
7.5
0.5
4
2-3
po
DVT
MC
MC
MC
RN CN
RN CN
Dr Marevan
2310
  • On day four you measure his INR at 8am and the
    results return as 4.1
  • Fill out the chart provided to reflect this
    information, and provide a dose based on the age
    adjusted warfarin protocol

22
Case Study Two
30/10
1.1
1.8
1.6
4.1
7.5
0.5
4
w/h
2-3
1
po
DVT
MC
MC
MC
MC
MC
RN CN
RN CN
RN CN
RN CN
Dr Marevan
2310
  • Next days dose should be withheld then commence
    again in dose range 0.5mg 1.5mg
Write a Comment
User Comments (0)
About PowerShow.com